Journal profile · Biotechnology & Applied Microbiology
Current opinion in molecular therapeutics
ISSN 1464-8431 · ENGLAND · Bimonthly · Founded 1999
Current opinion in molecular therapeutics: impact factor 6.1 (journal website); subscription journal; review over 12 weeks (community reports); community-reported acceptance: moderate.
Scope
Aims, scope and focus
By OpenAlex counts of its recent articles, Current opinion in molecular therapeutics's largest topics are Virus-based gene therapy research, RNA Interference and Gene Delivery and Genetic Associations and Epidemiology, together about 44.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
A leader in open access publishing, BMC makes scientific knowledge widely available and champions the benefits of open research for all.BMC is committed to supporting the needs of our communities, safeguarding the integrity of the research we publish, and providing a comprehensive forum for sharing scientifically robust findings with the world.An open access pioneer In 2000, BMC (then BioMed Central) made high quality research open to every reader – and in making the open access model sustainable, we changed the world of academic publishing.We have consistently valued rigorous review and were one of the first publishers to have a dedicated research integrity team, building our reputation for publishing high-quality open access research.BMC continues to partner with authors, editors, and reviewers to make research more discoverable, and to develop new approaches to peer review to give authors an efficient, transparent, and fair process. Innovation in publishing - like research itself - never stops. BMC continues to experiment with and develop new approaches to research publishing, to better support researchers and their communities.Our journals and impact BMC has a portfolio of more than 300 peer-reviewed journals, sharing discoveries from research communities across scientific and clinical disciplines.Some of our journals were the very first open access journals in their fields. Now they, and the journals we have launched in the years since, are some of the largest and most cited open access publications in their disciplines.With the support of over 23,000 editors, we’ve helped authors from more than 160 countries share their findings with the world. Together, we empower our research communities to drive meaningful change. Trusted We publish research held to the highest standards of scientific rigor, accessed by 6 million readers each month.1 Supportive In our author survey, 94% agreed that their review process was ‘detailed and informative’ and ‘useful in improving my manuscript’.2 Inclusive BMC welcomes all robust research, from groundbreaking discoveries to articles, data outputs and methodologies that support sound science and reproducibility. Community-focused We have built a loyal and diverse community of editors, reviewers and authors who play a vital role in ensuring a high standard of research integrity. Footnotes Based on Google Analytics site data from 2024.Springer Nature Journal Author Satisfaction survey, 2024.
From the journal's Aims & Scope
Research area (LetPub): Biotechnology & Applied Microbiology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology22.2%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology16.7%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology5.6%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics5.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.6%
- HER2/EGFR in Cancer ResearchMedicine5.6%
- Lysosomal Storage Disorders ResearchMedicine5.6%
- Monoclonal and Polyclonal Antibodies ResearchMedicine5.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 6.1Publisher website ·
- h-index
- 2OpenAlex ·
- i10-index
- 0OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Downloads per year (publisher) 2025
- 1,100,000Publisher website ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Submission to first decision
- 9 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
Publisher websitePolicy excerpts from the journal's websiteOpen access
- Open access An open access pioneer
In 2000, BMC (then BioMed Central) made high quality research open to every reader – and in making the open access model sustainable, we changed the world of academic publishing. We have consistently valued rigorous review and were one of the first publishers to have a dedicated research integrity team, building our reputation for publishing high-quality open access research. BMC continues to part…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Country or region
- ENGLAND
- Frequency
- Bimonthly
- Founded
- 1999
- ISSN
- 1464-8431
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Current opinion in molecular therapeutics
What is the impact factor of Current opinion in molecular therapeutics?
The journal's website gives an impact factor of 6.1 (2025); this is the journal's own figure, as LetPub lists none for it; h-index 2.
How long does peer review take at Current opinion in molecular therapeutics?
Authors report an average review time of over 12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Is Current opinion in molecular therapeutics open access, and what is the APC?
Current opinion in molecular therapeutics is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .